Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$2.52
-HK$0.02(-0.79%)
At close: 4:00 PM EDT
HK$2.52
-HK$0.02(-0.79%)
Day’s Range― - ―
52-Week RangeHK$1.97 - HK$4.95
Previous CloseN/A
Volume865.87K
Average Volume (3M)6.34M
Market Cap
HK$2.18B
Enterprise ValueHK$2.19K
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$301.80M
Price to Earnings (P/E)1.8
Beta1.40
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)HK$1.04B
Bulls Say, Bears Say
Bulls Say
First-in-class ProductHaving a first-in-class glucokinase activator creates durable competitive differentiation in China’s large T2D market. This status supports premium positioning, incentivizes physician adoption, and enables future indication expansion or partnerships, sustaining commercial tailwinds beyond short-term cycles.
Revenue Growth & Margin ImprovementAccelerating top-line and materially higher gross margins indicate improving product economics and stronger demand. If maintained, these trends can compress the gap to operating profitability and provide runway to fund SG&A and R&D without immediate capital raises, supporting sustainable commercial scale.
Improved Balance-sheet LeverageA manageable debt-to-equity and restored positive equity provide financial flexibility to fund commercialization and pipeline investment. Compared with prior-year weakness, this improvement reduces insolvency risk and increases ability to access capital or tolerate temporary cash burn while pursuing long-term growth.
Bears Say
Negative Operating Cash FlowSustained negative operating and free cash flow increases dependency on external financing or asset sales to fund ongoing commercialization and R&D. Cash conversion weakness versus net income raises risk that profitable reporting may not translate into sustainable liquidity, constraining strategic options.
Ongoing Operating LossesDespite revenue gains, deeply negative operating and EBITDA margins show the core business has not reached structural profitability. Persistent operating losses mean long-term viability depends on reducing costs or achieving much larger scale, increasing execution risk for durable earnings improvement.
Earnings Quality VolatilityA positive net result driven by non-operating items undermines predictability of earnings and can mask weak operational performance. This volatility in reported profits and equity swings reduces confidence in repeatable cash-generating ability and complicates long-term planning and investor assessment.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.97 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$2.18B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 19 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.634%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
2552 Company Deck
2552 Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―